07:00 , Jun 26, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer c-Myc (MYC); phosphoribosyl pyrophosphate synthetase 2 (PRPS2) Mouse studies suggest inhibiting PRPS2 could help treat cancers driven by MYC. In a Myc-dependent mouse model...
07:00 , Jun 19, 2014 |  BC Innovations  |  Cover Story

Breaking MYC metabolism

The metabolic enzyme phosphoribosyl pyrophosphate synthetase 2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC. 1 The findings from a University of California, San Francisco team are licensed to Effector Therapeutics...